All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study.

The primary outcome of the study was the attainment of low disease activity at week 12, defined as a C-reactive protein (CRP) polymyalgia rheumatica activity score (PMR-AS) of 10 or less without oral ...

Polymyalgia rheumatica (PMR) is accepted as being the most common inflammatory disease in persons over the age of 50 years of European descent. The clinical features of PMR are myriad, and each of ...